Ubix Therapeutics
PrivateLast Round
Growth Equity
Dec 23, 2024
Total Funding Raised
$46.3M
Company Overview
Ubix Therapeutics is a biotechnology company that develops novel anti-cancer therapies using its proprietary targeted protein degradation platform, Degraducer®.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ubix Therapeutics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Ubix Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Dec 23, 2024 | ||||
| Series C | Jul 1, 2023 | ||||
| Series B | May 6, 2020 | ||||
| Series A | Feb 1, 2019 |
Ubix Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KOTEC | Growth Equity |
| BNH INVESTMENT | Series C |
| UTC Investment | Series B, Series C |
| Premier Partners | Series B, Series A |
| QUAD Investment Management | Growth Equity |
| GeneN Investment Partners | Series C |
| Medytox Venture Investment | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 6, 2020
$12.2M raised from Premier Partners and UTC Investment.
Ubix Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Ubix Therapeutics's valuation, stock price, and market status.